Skip to content

Studying the Modification of Attention Bias Remotely After Trauma

Optimizing Attention Bias Modification for Posttraumatic Stress Disorder: An Entirely Remote Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04888169
Acronym
SMART
Enrollment
1314
Registered
2021-05-17
Start date
2023-04-20
Completion date
2025-06-30
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Traumatic Stress Disorder

Keywords

Attention bias

Brief summary

The investigators will complete an entirely remote randomized controlled trial (RCT) comparing 14 sessions of attention bias modification (ABM), attention control training (ACT), placebo neutral attention training, and a final control condition with daily questions in 1,897 individuals with clinically significant Post-traumatic Stress Symptoms (PTSS) (defined as PCL-5 score ≥ 33). To assess effects of the training and control conditions, the investigators will administer tests of threat-related attention bias and variability, and self-report assessments of PTSS, depression, anxiety, and perceived stress at baseline, after one and two weeks of training, and at eight-week follow up. The investigators plan to screen and confirm interest from over 3,000 eligible participants over a period of 24 months to enroll and randomize 1,897 participants with the end goal of 1,232 completers (176 per condition).

Interventions

DEVICESMART Mobile App - Attention Bias Modification

ABM involves placing the probe behind the neutral stimulus on 100% of the trials.

DEVICESMART Mobile App - Attention Control Training

ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.

DEVICESMART Mobile App - Placebo Training

Placebo training only includes neutral stimuli.

DEVICESMART Mobile App - Control

Participants will only answer questions.

Sponsors

University of California, San Francisco
Lead SponsorOTHER
San Francisco Veterans Affairs Medical Center
CollaboratorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18 to 65 years * Score at or above 33 on the PCL-5, * Able and willing to perform daily smartphone training for two weeks * Fluent English comprehension. * Owns Android or iPhone smartphone

Exclusion criteria

* Does not have Android or iPhone Operating System (iOS) smartphone running sufficient software (i.e. at least iOS 10.1), and is not willing to update * Active suicidality.

Design outcomes

Primary

MeasureTime frameDescription
Change in PTSD Checklist-5 (PCL) Score (Before/After Training)Baseline, 4 weeksLooking at the change of PCL scores from prior to beginning (baseline) and directly after completing the training at week 4. PCL scores range from 0-80 with a score of 33 indicating clinically significant levels of PTSD. A 10 point change (up or down) is considered a clinically significant change in PTSD symptoms. A PCL score of \<33 indicates non-clinically significant PTSS. A PCL score of \>= 33 indicates clinically significant PTSS.
Change in PTSD Checklist-5 (PCL) Score (Follow-up)4 weeks, 8 WeeksLooking at the change of PCL scores from directly after completing the training at 4 weeks to a follow-up conducted at week 8. PCL scores range from 0-80 with a score of 33 indicating clinically significant levels of PTSD. A 10 point change (up or down) is considered a clinically significant change in PTSD symptoms. A PCL score of \<33 indicates non-clinically significant PTSS. A PCL score of \>= 33 indicates clinically significant PTSS.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJoshua Woolley, MD, PhD

UCSF, SFVAMC

PRINCIPAL_INVESTIGATORJoaquin Anguera, PhD

University of California, San Francisco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026